Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. more
Time Frame | LEXX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.83% | -3.39% | -3.47% |
1-Month Return | 0.96% | -3.25% | -0.29% |
3-Month Return | -34.47% | -11.61% | 4.5% |
6-Month Return | -28.96% | -5.89% | 6.91% |
1-Year Return | 49.65% | 2.65% | 23.79% |
3-Year Return | -49.28% | 0.56% | 28.43% |
5-Year Return | -82.42% | 34.63% | 83.64% |
10-Year Return | -14.02% | 94.78% | 185.94% |
Aug '20 | Aug '21 | Aug '22 | Aug '23 | Aug '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 384.54K | 722.74K | 255.40K | 226.21K | 464.28K | [{"date":"2020-08-31","value":53.21,"profit":true},{"date":"2021-08-31","value":100,"profit":true},{"date":"2022-08-31","value":35.34,"profit":true},{"date":"2023-08-31","value":31.3,"profit":true},{"date":"2024-08-31","value":64.24,"profit":true}] |
Cost of Revenue | 99.38K | 175.35K | 71.84K | 31.50K | 4.82K | [{"date":"2020-08-31","value":56.68,"profit":true},{"date":"2021-08-31","value":100,"profit":true},{"date":"2022-08-31","value":40.97,"profit":true},{"date":"2023-08-31","value":17.96,"profit":true},{"date":"2024-08-31","value":2.75,"profit":true}] |
Gross Profit | 285.17K | 547.39K | 183.56K | 194.71K | 459.46K | [{"date":"2020-08-31","value":52.1,"profit":true},{"date":"2021-08-31","value":100,"profit":true},{"date":"2022-08-31","value":33.53,"profit":true},{"date":"2023-08-31","value":35.57,"profit":true},{"date":"2024-08-31","value":83.94,"profit":true}] |
Gross Margin | 74.16% | 75.74% | 71.87% | 86.07% | 98.96% | [{"date":"2020-08-31","value":74.94,"profit":true},{"date":"2021-08-31","value":76.53,"profit":true},{"date":"2022-08-31","value":72.63,"profit":true},{"date":"2023-08-31","value":86.98,"profit":true},{"date":"2024-08-31","value":100,"profit":true}] |
Operating Expenses | 4.27M | 6.23M | 7.57M | 6.73M | 6.21M | [{"date":"2020-08-31","value":56.47,"profit":true},{"date":"2021-08-31","value":82.38,"profit":true},{"date":"2022-08-31","value":100,"profit":true},{"date":"2023-08-31","value":88.92,"profit":true},{"date":"2024-08-31","value":82.1,"profit":true}] |
Operating Income | (3.89M) | (5.69M) | (7.38M) | (6.53M) | (5.75M) | [{"date":"2020-08-31","value":-389195100,"profit":false},{"date":"2021-08-31","value":-568685200,"profit":false},{"date":"2022-08-31","value":-738365300,"profit":false},{"date":"2023-08-31","value":-653402200,"profit":false},{"date":"2024-08-31","value":-575313000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | (764.61K) | (135.31K) | - | [{"date":"2020-08-31","value":"-","profit":true},{"date":"2021-08-31","value":"-","profit":true},{"date":"2022-08-31","value":-76461400,"profit":false},{"date":"2023-08-31","value":-13531300,"profit":false},{"date":"2024-08-31","value":"-","profit":true}] |
Pre-Tax Income | (4.08M) | (4.16M) | (7.38M) | (6.71M) | (5.80M) | [{"date":"2020-08-31","value":-408461300,"profit":false},{"date":"2021-08-31","value":-416414800,"profit":false},{"date":"2022-08-31","value":-738365300,"profit":false},{"date":"2023-08-31","value":-671252500,"profit":false},{"date":"2024-08-31","value":-579534500,"profit":false}] |
Income Taxes | (54.29K) | (1.66M) | (114.33K) | 130.88K | - | [{"date":"2020-08-31","value":-41.48,"profit":false},{"date":"2021-08-31","value":-1268.25,"profit":false},{"date":"2022-08-31","value":-87.36,"profit":false},{"date":"2023-08-31","value":100,"profit":true},{"date":"2024-08-31","value":"-","profit":true}] |
Income After Taxes | - | - | (7.27M) | (6.84M) | - | [{"date":"2020-08-31","value":"-","profit":true},{"date":"2021-08-31","value":"-","profit":true},{"date":"2022-08-31","value":-726932400,"profit":false},{"date":"2023-08-31","value":-684340200,"profit":false},{"date":"2024-08-31","value":"-","profit":true}] |
Income From Continuous Operations | (4.08M) | (4.16M) | (7.38M) | (6.71M) | - | [{"date":"2020-08-31","value":-408461300,"profit":false},{"date":"2021-08-31","value":-416414800,"profit":false},{"date":"2022-08-31","value":-738365300,"profit":false},{"date":"2023-08-31","value":-671252500,"profit":false},{"date":"2024-08-31","value":"-","profit":true}] |
Income From Discontinued Operations | (22.00K) | (22.00K) | - | - | - | [{"date":"2020-08-31","value":-2200000,"profit":false},{"date":"2021-08-31","value":-2200000,"profit":false},{"date":"2022-08-31","value":"-","profit":true},{"date":"2023-08-31","value":"-","profit":true},{"date":"2024-08-31","value":"-","profit":true}] |
Net Income | (4.03M) | (2.50M) | (7.27M) | (6.66M) | (5.80M) | [{"date":"2020-08-31","value":-403032700,"profit":false},{"date":"2021-08-31","value":-250430200,"profit":false},{"date":"2022-08-31","value":-726932400,"profit":false},{"date":"2023-08-31","value":-666489900,"profit":false},{"date":"2024-08-31","value":-579534500,"profit":false}] |
EPS (Diluted) | (0.05) | (0.84) | (1.25) | (1.01) | (0.47) | [{"date":"2020-08-31","value":-5,"profit":false},{"date":"2021-08-31","value":-84,"profit":false},{"date":"2022-08-31","value":-125,"profit":false},{"date":"2023-08-31","value":-100.81,"profit":false},{"date":"2024-08-31","value":-47,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LEXX | |
---|---|
Cash Ratio | 5.96 |
Current Ratio | 7.18 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LEXX | |
---|---|
ROA (LTM) | -38.21% |
ROE (LTM) | -70.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LEXX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LEXX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 89.59 |
P/B | 4.58 |
Price/FCF | NM |
EV/R | 65.49 |
EV/Ebitda | NM |
Lexaria Bioscience Corp (LEXX) share price today is $2.1
Yes, Indians can buy shares of Lexaria Bioscience Corp (LEXX) on Vested. To buy Lexaria Bioscience Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LEXX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Lexaria Bioscience Corp (LEXX) via the Vested app. You can start investing in Lexaria Bioscience Corp (LEXX) with a minimum investment of $1.
You can invest in shares of Lexaria Bioscience Corp (LEXX) via Vested in three simple steps:
The 52-week high price of Lexaria Bioscience Corp (LEXX) is $6.85. The 52-week low price of Lexaria Bioscience Corp (LEXX) is $1.2.
The price-to-earnings (P/E) ratio of Lexaria Bioscience Corp (LEXX) is
The price-to-book (P/B) ratio of Lexaria Bioscience Corp (LEXX) is 4.58
The dividend yield of Lexaria Bioscience Corp (LEXX) is 0.00%
The market capitalization of Lexaria Bioscience Corp (LEXX) is $36.82M
The stock symbol (or ticker) of Lexaria Bioscience Corp is LEXX